Makoto Nishino

Makoto Nishino

Auto-generated profile, based on publicly available information

Makoto Nishino

Department of Pediatrics National Hospital Organization Sagamihara National Hospital Kanagawa Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2021 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
YMYoko Miura
Yoko Miura
KNKen-Ichi Nagakura
Ken-Ichi Nagakura
MNMakoto Nishino
Makoto Nishino
MTMari Takei
Mari Takei
KTKyohei Takahashi
Kyohei Takahashi
NYNoriyuki Yanagida
Noriyuki Yanagida

1 September 2020 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
KNKen‐Ichi Nagakura
Ken‐Ichi Nagakura
SSSakura Sato
Sakura Sato
YMYoko Miura
Yoko Miura
MNMakoto Nishino
Makoto Nishino
KTKyohei Takahashi
Kyohei Takahashi
NYNoriyuki Yanagida
Noriyuki Yanagida
Background: Severe reactions may develop during cow's milk (CM) oral immunotherapy (OIT). We investigated the safety and efficacy of low‐dose OIT with heated milk (HM) or unheated milk (UM) in children with anaphylaxis.Methods: Children with symptom onset after ingestion of 3‐mL HM on a double‐blind, placebo‐controlled food challenge were randomly assigned to the HM (n = 17) or UM (n = 16) group. HM group ingested milk powder heated at 125°C for 30 seconds, whereas the UM group used UM. Patients were hospitalized for 5 days; the HM or UM was gradually increased to 3 mL/day; 3‐mL/day ingestion was continued at home. One year later, the patients underwent 2‐day consecutive 3‐ and 25‐mL HM‐oral food challenges (OFCs) after 2‐week avoidance.Results: At baseline, milk‐ and casein‐specific immunoglobulin E (IgE) levels were 56.0 and 51.4 kUA/L in the HM group, and 55.2 and 65.6 kUA/L in the UM group, respectively. One year later, 35% and 18% in the HM group and 50% and 31% in UM group passed the 3 and 25 mL OFCs, respectively. Rates of moderate or severe symptoms and respiratory symptoms per home dose were significantly lower in the HM than in the UM group (0.7% and 1.2% vs 1.4% and 2.6%, respectively, P < .001). β‐lactoglobulin‐specific IgG4 levels significantly increased from baseline only in the UM group, whereas casein‐specific IgG4 levels significantly increased from baseline in both groups.Conclusions: HM‐OIT induced immunological changes more safely than the UM‐OIT. The possibility of lower treatment efficacy with HM‐OIT needs to be evaluated in larger studies.

1 October 2019 in Allergology International
Verified
Journal Article
Open access
TMTetsuharu Manabe
Tetsuharu Manabe
SSSakura Sato
Sakura Sato
NYNoriyuki Yanagida
Noriyuki Yanagida
NHNoriko Hayashi
Noriko Hayashi
MNMakoto Nishino
Makoto Nishino
MEMotohiro Ebisawa
Motohiro Ebisawa

11 November 2020 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MNMakoto Nishino
Makoto Nishino
SSSakura Sato
Sakura Sato
KNKen-Ichi Nagakura
Ken-Ichi Nagakura
KTKyohei Takahashi
Kyohei Takahashi
TATomoyuki Asaumi
Tomoyuki Asaumi
NYNoriyuki Yanagida
Noriyuki Yanagida

11 December 2022 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
MNMakoto Nishino
Makoto Nishino
NYNoriyuki Yanagida
Noriyuki Yanagida
SSSakura Sato
Sakura Sato
KNKen‐Ichi Nagakura
Ken‐Ichi Nagakura
KTKyohei Takahashi
Kyohei Takahashi
MEMotohiro Ebisawa
Motohiro Ebisawa

4 November 2022 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
KTKyohei Takahashi
Kyohei Takahashi
NYNoriyuki Yanagida
Noriyuki Yanagida
TITakaaki Itonaga
Takaaki Itonaga
MNMakoto Nishino
Makoto Nishino
KNKen‐Ichi Nagakura
Ken‐Ichi Nagakura
MEMotohiro Ebisawa
Motohiro Ebisawa